Company / Capital Expenditures
Pfizer Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.6B
FY2025
5-year range
$2.0B / $2.9B
FY2021-FY2025
Trend
-9.6%
vs FY2024
Sector context
#3 of 194
Health Care
What the data says
Among 194 Health Care companies, Pfizer is in the top 2% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $1.2B in FY2016 to $2.9B in FY2024.
Based on SEC 10-K filings.
$2.6B in FY2025 with a 5-year CAGR of +3.4%. Ranks 3rd among 194 companies in Health Care.
Declined from $2.7B to $2.6B over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- +3.4%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 194This company $2.6B Sector average $117.5M
▼
+2137.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.4%, indicating consistent growth.
- In FY2025, capital expenditures decreased 9.6% year-over-year.
- Ranks #3 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.6B | -9.6% |
| FY2024 | $2.9B | +7.3% |
| FY2023 | $2.7B | +21.8% |
| FY2022 | $2.2B | +8.8% |
| FY2021 | $2.0B | -8.1% |
| FY2020 | $2.2B | +8.8% |
| FY2019 | $2.0B | +12.2% |
| FY2018 | $1.8B | +30.5% |
| FY2017 | $1.4B | +16.5% |
| FY2016 | $1.2B | -14.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026